CL2019003249A1 - Protocolo mejorado para el tratamiento de nefritis lúpica. - Google Patents

Protocolo mejorado para el tratamiento de nefritis lúpica.

Info

Publication number
CL2019003249A1
CL2019003249A1 CL2019003249A CL2019003249A CL2019003249A1 CL 2019003249 A1 CL2019003249 A1 CL 2019003249A1 CL 2019003249 A CL2019003249 A CL 2019003249A CL 2019003249 A CL2019003249 A CL 2019003249A CL 2019003249 A1 CL2019003249 A1 CL 2019003249A1
Authority
CL
Chile
Prior art keywords
treatment
lupus nephritis
improved protocol
protocol
improved
Prior art date
Application number
CL2019003249A
Other languages
English (en)
Inventor
Neil Solomons
Robert B Huizinga
Original Assignee
Aurinia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64095925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003249(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aurinia Pharmaceuticals Inc filed Critical Aurinia Pharmaceuticals Inc
Publication of CL2019003249A1 publication Critical patent/CL2019003249A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

AL EMPLEAR UN RÉGIMEN DE DOSIFICACIÓN FARMACODINÁMICO, LA EFECTIVIDAD DE UN PROTOCOLO PARA TRATAMIENTO DE UNA ENFERMEDAD RENAL PROTEINÚRICA CON VOCLOSPORINA SE PUEDE MAXIMIZAR MIENTRAS QUE SE MINIMIZAN LOS EFECTOS SECUNDARIOS INDESEABLES.
CL2019003249A 2017-05-12 2019-11-13 Protocolo mejorado para el tratamiento de nefritis lúpica. CL2019003249A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505734P 2017-05-12 2017-05-12
US201762541612P 2017-08-04 2017-08-04
US15/835,219 US10286036B2 (en) 2017-05-12 2017-12-07 Protocol for treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
CL2019003249A1 true CL2019003249A1 (es) 2020-07-10

Family

ID=64095925

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003249A CL2019003249A1 (es) 2017-05-12 2019-11-13 Protocolo mejorado para el tratamiento de nefritis lúpica.

Country Status (25)

Country Link
US (1) US10286036B2 (es)
EP (2) EP3634463B9 (es)
JP (4) JP7050904B2 (es)
KR (2) KR20240142619A (es)
CN (1) CN111163794A (es)
AU (2) AU2018266850B2 (es)
BR (1) BR112019023766A2 (es)
CA (1) CA3063040A1 (es)
CL (1) CL2019003249A1 (es)
DK (1) DK3634463T3 (es)
ES (1) ES2965454T3 (es)
FI (1) FI3634463T3 (es)
HR (1) HRP20231469T1 (es)
HU (1) HUE064984T2 (es)
IL (2) IL310731A (es)
LT (1) LT3634463T (es)
MX (1) MX2022014618A (es)
MY (1) MY203070A (es)
PL (1) PL3634463T3 (es)
PT (1) PT3634463T (es)
RS (1) RS64959B1 (es)
SI (1) SI3634463T1 (es)
SM (1) SMT202300407T1 (es)
WO (1) WO2018207026A2 (es)
ZA (1) ZA201907460B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CA3205359A1 (en) * 2021-01-15 2022-07-21 Michael Martin Protocol to minimize calcineurin inhibitor nephrotoxicity
US20240228644A1 (en) * 2021-05-04 2024-07-11 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
CA3219742A1 (en) * 2021-05-21 2022-11-24 Gabor Illei Cd40l antagonist and uses thereof in the treatment of lupus nephritis
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
IT202300028041A1 (it) * 2023-12-27 2025-06-27 Indena Spa Processo per la preparazione di voclosporina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712084A (en) 1995-09-08 1998-01-27 Research Corporation Technologies, Inc. Donor kidney viability test for improved preservation
DK1436322T3 (da) * 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler
HRP20070058B1 (hr) 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
EP1435910B9 (en) 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
PL1868635T3 (pl) 2005-04-06 2017-10-31 Bristol Myers Squibb Co Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4
US8628930B2 (en) * 2009-04-27 2014-01-14 Niigata University Use of megalin in urine as marker for detecting renal disorder
CA2788650C (en) 2010-02-02 2023-02-14 Kathrine P. Frey Methods and devices for reducing transfusions during or after surgery and for improving quality of life and function in chronic disease
JP5881721B2 (ja) * 2011-10-12 2016-03-09 Ｓｂｉファーマ株式会社 慢性腎臓病の改善・予防剤
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Also Published As

Publication number Publication date
WO2018207026A3 (en) 2019-02-07
KR20240142619A (ko) 2024-09-30
IL270552B1 (en) 2024-03-01
HRP20231469T1 (hr) 2024-03-01
JP2020519695A (ja) 2020-07-02
MX2022014618A (es) 2023-01-30
JP7050904B2 (ja) 2022-04-08
AU2024202977A1 (en) 2024-05-23
JP7295305B2 (ja) 2023-06-20
KR20200007884A (ko) 2020-01-22
CA3063040A1 (en) 2018-11-15
EP4257138A3 (en) 2024-01-03
NZ799751A (en) 2026-01-30
NZ759886A (en) 2026-01-30
RU2019140834A3 (es) 2021-08-25
JP2023113884A (ja) 2023-08-16
JP2022095754A (ja) 2022-06-28
AU2018266850A2 (en) 2020-02-06
PT3634463T (pt) 2023-12-05
AU2018266850B2 (en) 2024-02-08
IL310731A (en) 2024-04-01
BR112019023766A2 (pt) 2020-05-26
RU2019140834A (ru) 2021-06-15
WO2018207026A2 (en) 2018-11-15
IL270552A (en) 2020-01-30
EP3634463B1 (en) 2023-09-27
JP2025163248A (ja) 2025-10-28
AU2018266850A1 (en) 2020-01-02
EP3634463A2 (en) 2020-04-15
IL270552B2 (en) 2024-07-01
SI3634463T1 (sl) 2024-04-30
US10286036B2 (en) 2019-05-14
DK3634463T3 (da) 2023-11-27
EP3634463A4 (en) 2021-03-17
MY203070A (en) 2024-06-06
HUE064984T2 (hu) 2024-04-28
ZA201907460B (en) 2020-11-25
FI3634463T3 (fi) 2023-11-16
US20180325995A1 (en) 2018-11-15
ES2965454T3 (es) 2024-04-15
LT3634463T (lt) 2024-01-10
PL3634463T3 (pl) 2024-03-04
SMT202300407T1 (it) 2024-01-10
CN111163794A (zh) 2020-05-15
RS64959B1 (sr) 2024-01-31
EP3634463B9 (en) 2024-01-10
KR102710584B1 (ko) 2024-09-27
EP4257138A2 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
MX2022014618A (es) Protocolo mejorado para tratamiento de nefritis lupica.
CY1125170T1 (el) Δοσολογικο σχημα για την πονεσιμοδη, εναν επιλεκτικο αγωνιστη του υποδοχεα s1p1
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
UY36275A (es) Compuestos aminopirimidinilo
MX378735B (es) Moduladores de receptores de quimiocina
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MD3395821T2 (ro) Compuși antitumorali
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
MX2019009763A (es) Metodos para tratar esquizofrenia.
EA201792478A1 (ru) Соединения-ингибиторы передачи сигналов пути notch
EA201892430A1 (ru) Синтез индазолов
MX373268B (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
CL2018002583A1 (es) Derivado de morfolina
CO2019006234A2 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal
MA41481B1 (fr) Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MX2018002354A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
CL2018000508S1 (es) Cubierta posterior para moto scooter.
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX2019001781A (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
MX386975B (es) Fármacos precursores de oxabicicloheptanos.
CL2018000290A1 (es) Antagonistas del receptor de cgrp